Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Post by TheRock07on Sep 08, 2016 9:06am
293 Views
Post# 25217017

Skin Care Portfolio

Skin Care PortfolioAs part of the Crescita deal with valeant, four high-end medical skin care brands,   Knight  entered into an exclusive distribution, licence and supply agreement to commercialize all Intega's current and future products in Israel, Romania, Russia, sub-Saharan Africa and the Caribbean.

Current sales of these skin care products  in Canada { and mostly in Quebec ) are about $10 million.

Sales have stagnated due to neglect by Valeant, but the skin care market is very large and is growing rapidly.

The skin care market of I 
srael, Romania, Russia, sub-Saharan Africa and the Caribbean. is about 7 times ( $10 billion )  that of Canada, a market which offers considerable upside and which crescita will be expanding using both internal and external salesmen.

However, even considering current sales, Knight could expect combined sales in excess of $50 million from these skin care products within its licensed regions.

IMO, Crescita should be able to double sales in Canada, with its active direct and indirect sales efforts.

This opens the possibility that Knight could expect sales in excess of $100 million from these skin care products, once it activates its sales teams.

Average market cap peer valuation of junior healthcare stocks like GUD is about 7.5 times annual sales.

Without debt, this multiple expands to 10 10 times.

Its why, when its other extensive deals are integrated and considering over $600 million in cash, GUD is very undervalued at current levels
Bullboard Posts